M. Certo and V. Del-gaizo-moore, Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, vol.9, issue.5, pp.351-365, 2006.
DOI : 10.1016/j.ccr.2006.03.027

V. Fresquet, M. Rieger, C. Carolis, M. J. Garc-ia-barchino, and J. A. Martinez-climent, Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, issue.26, pp.4111-4119, 2014.
DOI : 10.1182/blood-2014-03-560284

L. J. Hogdal, B. J. Chyla, E. Mckeegan, J. Leverson, J. Potluri et al., BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, p.75, 2015.

G. Ichim, J. Lopez, S. U. Ahmed, N. Muthalagu, E. Giampazolias et al., Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death, Molecular Cell, vol.57, issue.5, pp.860-872, 2015.
DOI : 10.1016/j.molcel.2015.01.018

S. Kumar, R. Vij, J. L. Kaufman, J. Mikhael, T. Facon et al., Venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory multiple myeloma: phase I savety and efficacy, Haematologica, pp.100-658, 2015.

J. D. Leverson, H. Zhang, J. Chen, S. K. Tahir, D. C. Phillips et al., Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax), Cell Death and Disease, vol.15, issue.1, p.1590, 2015.
DOI : 10.1172/JCI39964

J. Ryan and A. Letai, BH3 profiling in whole cells by fluorimeter or FACS, Methods, vol.61, issue.2, pp.61-156, 2013.
DOI : 10.1016/j.ymeth.2013.04.006

A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, pp.202-208
DOI : 10.1038/leu.2009.151

C. Touzeau, C. Dousset, L. Gouill, S. Sampath, D. Leverson et al., The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma, Leukemia, vol.21, issue.1, pp.210-212
DOI : 10.1038/leu.2013.216

C. Touzeau, J. Ryan, J. Guerriero, P. Moreau, T. N. Chonghaile et al., BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics, Leukemia, vol.120, issue.3, pp.761-764, 2016.
DOI : 10.1016/j.ymeth.2013.04.006

URL : https://hal.archives-ouvertes.fr/inserm-01411102